Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

John McLaughlin,Vadim Markovtsov,Hui Li,Steve Wong,Marina Gelman,Yanhong Zhu,Christian Franci,D. Wayne Lang,Erlina Pali,Joe Lasaga,Caroline M. R. Low,Feifei Zhao,Betty Chang,Tarikere Gururaja,Weiduan Xu,Muhammad Baluom,David Sweeny,David L. Carroll,Arvinder Sran,Sambaiah Thota,Manjeet Parmer,Angela Romane,George Clemens,Elliott B. Grossbard,Kunbin Qu,Yonchu Jenkins,Taisei Kinoshita,Vanessa Taylor,Sacha Holland,Ankush Argade,Rajinder Singh,Polly Pine,Donald G. Payan,Yasumichi Hitoshi

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

2010

Purpose Aurora kinases play a key role in mitotic progression. Over-expression of Aurora kinases is found in several human cancers and correlated with histological malignancy and clinical outcomes. Therefore, Aurora kinase inhibitors should be useful in the treatment of cancers.

Keywords:

Protein kinase A
Aurora kinase
Protein kinase inhibitor
Tyrosine kinase
Kinase
Aurora inhibitor
Pathology
Phenotypic screening
Immunology
Malignancy
Biology
Internal medicine
Protein-Serine-Threonine Kinases
Cancer
Hematology
Cell cycle

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations